Last reviewed · How we verify
NCT00250055
Non-Invasive, Real-time Technology for Diagnosis of Cervical Tissue
NA trial testing Colposcopy, Spectroscopy, and Biopsy in Cervix in 100 participants. Terminated before completion.
1 December 2007
Quick facts
| Lead sponsor | University of New Mexico |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 April 2004 |
| Primary completion | 1 December 2007 |
| Estimated completion | 1 January 2010 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Colposcopy, Spectroscopy, and Biopsy
Conditions studied
Sponsor
University of New Mexico
Who can join
18 and older, female only, with Cervix or Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The objective of this study is to determine whether non-invasive measurements of light transport through tissue can identify pre-cancerous and cancerous conditions.
Time frame: 6 years
Sponsor's own description
In general, to determine the sensitivity of light transport to tissue from morphological features of clinical significance. Determine how specific structural features contribute to light scattering. Investigate light scattering differences in tumorigenic and nontumorigenic cells. Develop and implement quantitative and sensitive methods for measuring morphological properties. Clinical measurements.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00250055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of New Mexico trials
Trials by the same sponsor.
- NCT07484906 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies · Phase 2 · withdrawn
- NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting
- NCT07265973 — PREPARE: Perioperative REhabilitation Around Vaginal Prolapse RepAir Surgery for Recovery Enhancement · NA · recruiting
- NCT06982443 — Wellness, Alcohol, Vitals, and Emotions · NA · recruiting
- NCT06940609 — Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00250055 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of New Mexico
- Last refreshed: 9 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00250055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing